Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective Study

<b>Background:</b> the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis. <b>Methods:</b> this study included 11 patients (6 male, 5 female) who had previously received ixekizumab and then were switched to secukinumab. Patients' PASI, DLQI, and pain VAS (in those with psoriatic arthritis) were evaluated at weeks 16, 24, 54, and 98. <b>Results:</b> PASI-90 was reached in 10 (91%) cases at week 24. One patient experienced secondary failure to secukinumab at week 98. No adverse events were reported. <b>Conclusions:</b> overall, the majority of patients experienced a favorable response to secukinumab, suggesting that it may be an effective treatment option for patients with an inadequate response or loss of efficacy to ixekizumab.

Authors

Institutions

Publication Details

Journal
Journal of Personalized Medicine
Published
2024-12-22
DOI
https://doi.org/10.3390/jpm14121169
Citations
4
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.96
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective Study

Annunziata Dattola, Nicoletta Bernardini, Paolo Amerio, Nevena Skroza et al.
4 citations
Journal of Personalized Medicine
Psoriasis: Treatment and Pathogenesis
0.96
article

Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective Study

Annunziata Dattola, Nicoletta Bernardini, Paolo Amerio, Nevena Skroza, Antonio Giovanni Richetta, L Guacci, Concetta Potenza, Laura Atzori, Cristina Mugheddu, Gianluca Pagnanelli, Viviana Lora, Domenico Giordano, Severino Persechino, Raimondo Rossi
article en
4 citations

Abstract

<b>Background:</b> the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis. <b>Methods:</b> this study included 11 patients (6 male, 5 female) who had previously received ixekizumab and then were switched to secukinumab. Patients' PASI, DLQI, and pain VAS (in those with psoriatic arthritis) were evaluated at weeks 16, 24, 54, and 98. <b>Results:</b> PASI-90 was reached in 10 (91%) cases at week 24. One patient experienced secondary failure to secukinumab at week 98. No adverse events were reported. <b>Conclusions:</b> overall, the majority of patients experienced a favorable response to secukinumab, suggesting that it may be an effective treatment option for patients with an inadequate response or loss of efficacy to ixekizumab.

Journal of Personalized MedicineVol. 14(12)
University of Cagliari (IT), University of Chieti-Pescara (IT), Istituto Dermopatico dell'Immacolata (IT), San Gallicano Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Sapienza University of Rome (IT)
Good health and well-being
Openalex Percentile: Top 23%
Psoriasis: Treatment and Pathogenesis
0.96
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.